Keith C. Regnante
Net Worth
Last updated:
What is Keith C. Regnante net worth?
The estimated net worth of Mr. Keith C. Regnante is at least $4,750,375 as of 4 Jan 2024. He owns shares worth $37,396 as insider, has earned $3,675,839 from insider trading and has received compensation worth at least $1,037,140 in Keros Therapeutics, Inc..
What is the salary of Keith C. Regnante?
Mr. Keith C. Regnante salary is $518,570 per year as Chief Financial Officer in Keros Therapeutics, Inc..
How old is Keith C. Regnante?
Mr. Keith C. Regnante is 55 years old, born in 1970.
What stocks does Keith C. Regnante currently own?
As insider, Mr. Keith C. Regnante owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | Chief Financial Officer | 2,579 | $14.5 | $37,396 |
What does Keros Therapeutics, Inc. do?
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Keith C. Regnante insider trading
Keros Therapeutics, Inc.
Mr. Keith C. Regnante has made 6 insider trades between 2023-2024, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 40,000 units of KROS stock on 4 Nov 2023. As of 4 Jan 2024 he still owns at least 2,579 units of KROS stock.
Keros Therapeutics key executives
Keros Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Jasbir Seehra Ph.D. (70) Pres, Chief Executive Officer, Treasurer, & Director
- Dr. Jennifer Lachey Ph.D. (53) Chief Scientific Officer
- Mr. Keith C. Regnante (55) Chief Financial Officer